IMFINZI Market Summary

Key Factors Driving IMFINZI Growth

1. Broadening indications across multiple high-value cancers: IMFINZI (durvalumab), an anti-PD-L1 monoclonal antibody, has evolved from a primarily lung-cancer-focused product into a broad oncology franchise spanning NSCLC, SCLC, biliary tract cancer, hepatocellular carcinoma, endometrial cancer and bladder cancer. In the US, recent expansions include resectable NSCLC in 2024, limited-stage SCLC in December 2024, and muscle-invasive bladder cancer in March 2025. These additional indications materially enlarge the addressable patient pool and provide new sources of revenue beyond the mature unresectable Stage III NSCLC market.

2. Strong clinical differentiation in limited-stage SCLC: The ADRIATIC Phase III results provide an important new growth avenue. In 730 patients with LS-SCLC whose disease had not progressed after chemoradiotherapy, durvalumab reduced the risk of death by 27% (HR 0.73) versus placebo; median overall survival was 55.9 months versus 33.4 months, while progression-free survival was also significantly improved (HR 0.76). FDA approval in December 2024 creates an opportunity to establish IMFINZI as a standard consolidation treatment in a setting with substantial unmet need.

3. Expansion into earlier-stage disease is increasing treatment duration and patient reach: The AEGEAN and NIAGARA programs are shifting IMFINZI toward perioperative treatment, where patients can receive therapy both before and after surgery. FDA approved IMFINZI plus platinum chemotherapy as neoadjuvant therapy followed by adjuvant IMFINZI for resectable NSCLC in 2024, while NIAGARA supported approval in MIBC in 2025. The latter was based on a large Phase III study of 1,063 patients. Earlier-stage treatment potentially increases the number of eligible patients and duration of exposure compared with metastatic-only use.

4. Continued strength of the established lung and GI franchises: IMFINZI already has established positions in unresectable Stage III NSCLC, extensive-stage SCLC, biliary tract cancer and unresectable HCC, providing a diversified revenue base. Its combination strategies are particularly important: IMFINZI is used with chemotherapy in SCLC and BTC and with tremelimumab (IMJUDO) in HCC and selected NSCLC settings. This combination-based strategy enables AstraZeneca to extend the drug across different disease stages and biological settings rather than relying on monotherapy alone.

5. Large future opportunity from bladder-cancer expansion: Bladder cancer is emerging as one of IMFINZI's important next growth pillars. Beyond the 2025 MIBC approval, the FDA in May 2026 approved IMFINZI plus BCG for BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on the Phase III POTOMAC study involving 1,018 patients. This creates access to an earlier and substantially broader bladder-cancer population. AstraZeneca is also advancing the VOLGA program evaluating IMFINZI-based approaches in MIBC, supporting further lifecycle expansion.

IMFINZI Recent Developments

In May 2026, the Food and Drug Administration approved durvalumab (IMFINZI, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).

“IMFINZI Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of IMFINZI for approved indication like Bladder cancer, Non-small cell lung cancer, Small cell lung cancer, Biliary cancer; as well as potential indication like Cervical cancer, Fallopian tube cancer, Head and neck cancer, Malignant-mesothelioma, Peritoneal cancer, and Ovarian cancer in the 7MM. A detailed picture of IMFINZI’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the IMFINZI for approved and potential indications. The IMFINZI market report provides insights about IMFINZI’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current IMFINZI performance, future market assessments inclusive of the IMFINZI market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of IMFINZI sales forecasts, along with factors driving its market.

IMFINZI Drug Summary

AstraZeneca’s IMFINZI (Durvalumab) is a human monoclonal antibody and immune checkpoint inhibitor that targets programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 to restore T-cell-mediated anti-tumor immune responses. It is administered by intravenous infusion and is approved across multiple cancer indications, including unresectable Stage III non-small cell lung cancer (NSCLC), extensive-stage small cell lung cancer (ES-SCLC), biliary tract cancer (BTC), hepatocellular carcinoma (HCC), and certain endometrial and other solid tumors, depending on the specific treatment combination and regulatory jurisdiction. IMFINZI is used both as monotherapy and in combination with chemotherapy or other immunotherapies, with its clinical value driven by durable immune-mediated tumor control and expanding use across earlier-stage and metastatic settings. The report provides IMFINZI’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the IMFINZI Market Report

The report provides insights into:

• A comprehensive product overview including the IMFINZI MoA, description, dosage and administration, research and development activities in approved indications like Bladder cancer, Non-small cell lung cancer, Small cell lung cancer, Biliary cancer; as well as potential indication like Cervical cancer, Fallopian tube cancer, Head and neck cancer, Malignant-mesothelioma, Peritoneal cancer, and Ovarian cancer.
• Elaborated details on IMFINZI regulatory milestones and other development activities have been provided in IMFINZI market report.
• The report also highlights IMFINZI‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The IMFINZI market report also covers the patents information, generic entry and impact on cost cut.
• The IMFINZI market report contains current and forecasted IMFINZI sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The IMFINZI market report also features the SWOT analysis with analyst views for IMFINZI in approved and potential indications.

Methodology

The IMFINZI market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

IMFINZI Analytical Perspective by DelveInsight

• In-depth IMFINZI Market Assessment

This IMFINZI sales market forecast report provides a detailed market assessment of IMFINZI for approved indication like Bladder cancer, Non-small cell lung cancer, Small cell lung cancer, Biliary cancer; as well as potential indication like Cervical cancer, Fallopian tube cancer, Head and neck cancer, Malignant-mesothelioma, Peritoneal cancer, and Ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted IMFINZI sales data uptil 2034.

• IMFINZI Clinical Assessment

The IMFINZI market report provides the clinical trials information of IMFINZI for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

IMFINZI Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

IMFINZI Market Potential & Revenue Forecast

• Projected market size for the IMFINZI and its key indications
• Estimated IMFINZI sales potential (IMFINZI peak sales forecasts)
• IMFINZI Pricing strategies and reimbursement landscape

IMFINZI Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• IMFINZI Market positioning compared to existing treatments
• IMFINZI Strengths & weaknesses relative to competitors

IMFINZI Regulatory & Commercial Milestones

• IMFINZI Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

IMFINZI Clinical Differentiation

• IMFINZI Efficacy & safety advantages over existing drugs
• IMFINZI Unique selling points

IMFINZI Market Report Highlights

• In the coming years, the IMFINZI market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The IMFINZI companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IMFINZI’s dominance.
• Other emerging products for Bladder cancer, Non-small cell lung cancer, Small cell lung cancer, Biliary cancer; as well as potential indication like Cervical cancer, Fallopian tube cancer, Head and neck cancer, Malignant-mesothelioma, Peritoneal cancer, and Ovarian cancer are expected to give tough market competition to IMFINZI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IMFINZI in approved and potential indications.
• Analyse IMFINZI cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted IMFINZI sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of IMFINZI in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of IMFINZI? How strong is IMFINZI’s clinical and commercial performance?
• What is IMFINZI’s clinical trial status in each individual indications such as Bladder cancer, Non-small cell lung cancer, Small cell lung cancer, Biliary cancer; as well as potential indication like Cervical cancer, Fallopian tube cancer, Head and neck cancer, Malignant-mesothelioma, Peritoneal cancer, and Ovarian cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IMFINZI Manufacturers?
• What are the key designations that have been granted to IMFINZI for approved and potential indications? How are they going to impact IMFINZI’s penetration in various geographies?
• What is the current and forecasted IMFINZI market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of IMFINZI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to IMFINZI for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is IMFINZI? What is the duration of therapy and what are the geographical variations in cost per patient?